Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID.

Autor:	Grady CB; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Bhattacharjee B; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.; Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA., Silva J; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut., Jaycox J; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut., Lee LW; Adaptive Biotechnologies, Seattle, WA, USA., Monteiro VS; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut., Sawano M; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut., Massey D; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut., Caraballo C; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut., Gehlhausen JR; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut., Tabachnikova A; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut., Mao T; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut., Lucas C; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut., Peña-Hernandez MA; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.; Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA., Xu L; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut., Tzeng TJ; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut., Takahashi T; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut., Herrin J; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut., Güthe DB; Survivor Corps., Akrami A; Sainsbury Wellcome Centre, University College London, London, UK.; Patient-Led Research Collaborative., Assaf G; Patient-Led Research Collaborative., Davis H; Patient-Led Research Collaborative., Harris K; Survivor Corps., McCorkell L; Patient-Led Research Collaborative., Schulz WL; Center for Infection and Immunity, Yale School of Medicine, New Haven, Connecticut.; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.; Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut., Grffin D; Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York City, New York., Wei H; Patient-Led Research Collaborative., Ring AM; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut., Guan L; Center for Infection and Immunity, Yale School of Medicine, New Haven, Connecticut.; Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut., Cruz CD; Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA.; Center for Infection and Immunity, Yale School of Medicine, New Haven, Connecticut.; Department of Medicine, Section of Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut., Iwasaki A; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.; Center for Infection and Immunity, Yale School of Medicine, New Haven, Connecticut.; Howard Hughes Medical Institute, Chevy Chase, Maryland., Krumholz HM; Center for Infection and Immunity, Yale School of Medicine, New Haven, Connecticut.; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.; Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Jazyk:	angličtina
Zdroj:	MedRxiv : the preprint server for health sciences [medRxiv] 2024 Jan 12. Date of Electronic Publication: 2024 Jan 12.
DOI:	10.1101/2024.01.11.24300929
Abstrakt:	Background: Long COVID contributes to the global burden of disease. Proposed root cause hypotheses include the persistence of SARS-CoV-2 viral reservoir, autoimmunity, and reactivation of latent herpesviruses. Patients have reported various changes in Long COVID symptoms after COVID-19 vaccinations, leaving uncertainty about whether vaccine-induced immune responses may alleviate or worsen disease pathology. Methods: In this prospective study, we evaluated changes in symptoms and immune responses after COVID-19 vaccination in 16 vaccine-naïve individuals with Long COVID. Surveys were administered before vaccination and then at 2, 6, and 12 weeks after receiving the first vaccine dose of the primary series. Simultaneously, SARS-CoV-2-reactive TCR enrichment, SARS-CoV-2-specific antibody responses, antibody responses to other viral and self-antigens, and circulating cytokines were quantified before vaccination and at 6 and 12 weeks after vaccination. Results: Self-report at 12 weeks post-vaccination indicated 10 out of 16 participants had improved health, 3 had no change, 1 had worse health, and 2 reported marginal changes. Significant elevation in SARS-CoV-2-specific TCRs and Spike protein-specific IgG were observed 6 and 12 weeks after vaccination. No changes in reactivities were observed against herpes viruses and self-antigens. Within this dataset, higher baseline sIL-6R was associated with symptom improvement, and the two top features associated with non-improvement were high IFN-β and CNTF, among soluble analytes. Conclusions: Our study showed that in this small sample, vaccination improved the health or resulted in no change to the health of most participants, though few experienced worsening. Vaccination was associated with increased SARS-CoV-2 Spike protein-specific IgG and T cell expansion in most individuals with Long COVID. Symptom improvement was observed in those with baseline elevated sIL-6R, while elevated interferon and neuropeptide levels were associated with a lack of improvement.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu